Companies › Avidity Biosciences
3 active drug programs in 4 registered trials: 2 Phase 3, 2 Phase 2; Neurology, Immunology; next expected readout Apr 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| AOC 1044 antisense oligonucleotide for exon 44 skipping | DMD | Phase 3 | Muscular Dystrophies; DMD | Apr 2027 |
| AOC-1020 (Del-brax) Antisense oligonucleotide targeting DUX4 mRNA | DUX4 | Phase 3 | Facioscapulohumeral Muscular Dystrophy | May 2028 |
| AOC 1020 Antisense oligonucleotide targeting DUX4 mRNA | DUX4 | Phase 2 | FSHD | Apr 2030 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06244082 | AOC 1044 | Phase 2 | DMD | Neurology | Apr 2027 |
| NCT07038200 | AOC-1020 (Del-brax) | Phase 3 | Facioscapulohumeral Muscular Dystrophy | Neurology | May 2028 |
| NCT07587242 | AOC 1044 | Phase 3 | Muscular Dystrophies | Neurology | May 2029 |
| NCT06547216 | AOC 1020 | Phase 2 | FSHD | Immunology | Apr 2030 |
NS Pharma Nippon Shinyaku Sarepta Therapeutics Suven Life Sciences Shanghai Hutchison Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.